L Dobson1, C D Sheldon, A T Hattersley. 1. Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Peninsular Medical School, Barrack Road, Exeter EX2 5AX, UK.
Abstract
AIMS: Diabetes mellitus is an increasingly important complication of cystic fibrosis (CF). The association with increased morbidity of cystic fibrosis-related diabetes (CFRD) has emphasized the need for accurate monitoring of glycaemia in all CF patients. The diagnosis has relied on conventional thresholds in an oral glucose tolerance test (OGTT) derived from epidemiological studies in non-CF subjects. However, it has not been established if these values are equivalent in CF and non-CF populations. METHODS: We compared glycaemia in 21 non-diabetic CF subjects with 21-age and BMI-matched non-CF controls using HbA(1c), OGTT and a subcutaneous continuous glucose monitoring system (CGMS) that measures interstitial glucose levels. RESULTS: All conventional measures of glycaemia were similar in the two groups: HbA(1c) mean CF vs. controls (5.5 vs. 5.3%P = 0.4), fasting glucose (4.8 vs. 4.7 mmol/l P = 0.7) and 2-h glucose (5.8 vs. 5.7 mmol/l P = 0.8). However, these conventional measures did not accurately reflect glycaemia 30-, 60- and 90-min. Glucose values and area under the curve in OGTT were all higher in CF subjects than controls (P = 0.01-0.0001). Mean CGMS value [5.9 (0.8) vs. 5.1 (0.5) mmol/l, P = 0.004], and the proportion of subjects with peak CGMS values > 11.1 mmol/l (33 vs. 5%P = 0.00001) were also higher in CF subjects than controls. These results remained significantly different when only subjects with normal glucose tolerance in the two groups were studied. CONCLUSIONS: We have shown that overall glycaemia, as shown by both the response during an OGTT and CGMS, is higher in CF subjects who have similar HbA(1c), fasting and 2-h glucose values. These results question whether it is appropriate to use the diagnostic thresholds and OGTT time points derived from the non-CF population for a diagnosis of diabetes in patients with cystic fibrosis.
AIMS: Diabetes mellitus is an increasingly important complication of cystic fibrosis (CF). The association with increased morbidity of cystic fibrosis-related diabetes (CFRD) has emphasized the need for accurate monitoring of glycaemia in all CF patients. The diagnosis has relied on conventional thresholds in an oral glucose tolerance test (OGTT) derived from epidemiological studies in non-CF subjects. However, it has not been established if these values are equivalent in CF and non-CF populations. METHODS: We compared glycaemia in 21 non-diabetic CF subjects with 21-age and BMI-matched non-CF controls using HbA(1c), OGTT and a subcutaneous continuous glucose monitoring system (CGMS) that measures interstitial glucose levels. RESULTS: All conventional measures of glycaemia were similar in the two groups: HbA(1c) mean CF vs. controls (5.5 vs. 5.3%P = 0.4), fasting glucose (4.8 vs. 4.7 mmol/l P = 0.7) and 2-h glucose (5.8 vs. 5.7 mmol/l P = 0.8). However, these conventional measures did not accurately reflect glycaemia 30-, 60- and 90-min. Glucose values and area under the curve in OGTT were all higher in CF subjects than controls (P = 0.01-0.0001). Mean CGMS value [5.9 (0.8) vs. 5.1 (0.5) mmol/l, P = 0.004], and the proportion of subjects with peak CGMS values > 11.1 mmol/l (33 vs. 5%P = 0.00001) were also higher in CF subjects than controls. These results remained significantly different when only subjects with normal glucose tolerance in the two groups were studied. CONCLUSIONS: We have shown that overall glycaemia, as shown by both the response during an OGTT and CGMS, is higher in CF subjects who have similar HbA(1c), fasting and 2-h glucose values. These results question whether it is appropriate to use the diagnostic thresholds and OGTT time points derived from the non-CF population for a diagnosis of diabetes in patients with cystic fibrosis.
Authors: Quinn Dufurrena; Farhad M Amjad; Philipp E Scherer; Louis M Weiss; Jyothi Nagajyothi; Jesse Roth; Herbert B Tanowitz; Regina Kuliawat Journal: Parasitol Res Date: 2016-12-24 Impact factor: 2.289
Authors: M E Street; C Spaggiari; M A Ziveri; M Rossi; C Volta; I Viani; G L Grzincich; C Sartori; M Zanzucchi; V Raia; C Terzi; G Pisi; E Zanetti; M C S Boguszewski; T O Kamoi; S Bernasconi Journal: J Endocrinol Invest Date: 2011-04-06 Impact factor: 4.256
Authors: Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis Journal: Diabetes Care Date: 2010-12 Impact factor: 19.112
Authors: Christine L Chan; Timothy Vigers; Laura Pyle; Philip S Zeitler; Scott D Sagel; Kristen J Nadeau Journal: J Cyst Fibros Date: 2018-03-23 Impact factor: 5.482
Authors: Stephen M P O'Riordan; Peter Hindmarsh; Nathan R Hill; David R Matthews; Sherly George; Peter Greally; Gerard Canny; Dubhfeasa Slattery; Nuala Murphy; Edna Roche; Colm Costigan; Hilary Hoey Journal: Diabetes Care Date: 2009-03-11 Impact factor: 19.112
Authors: Shihab Hameed; John R Morton; Adam Jaffé; Penny I Field; Yvonne Belessis; Terence Yoong; Tamarah Katz; Charles F Verge Journal: Diabetes Care Date: 2009-11-12 Impact factor: 19.112